Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Guarneri · SciRah

Researcher profile · Semantic Scholar

V. Guarneri

Share profile

V. Guarneri — researcher profile on SciRah

h-index: 53
Works: 367
Citations: 11K

Most-cited papers

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
N. Harbeck, E. Ciruelos, G. Jerusalem, V. Müller +18 more
2024Nature Medicine236 citations Open access
Semantic Scholar
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
S. Loi, R. Salgado, G. Curigliano, Roberto Iván Romero Díaz +22 more
2025Nature Medicine117 citations Open access
Semantic Scholar
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
M. V. van Mackelenbergh, S. Loibl, M. Untch, M. Buyse +25 more
2023Journal of Clinical Oncology71 citations
Semantic Scholar
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
R. Dent, F. André, A. Gonçalves, M. Martín +22 more
2024Annals of Oncology65 citations Open access
Semantic Scholar
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Arianna Dri, G. Arpino, G. Bianchini, G. Curigliano +11 more
2023Cancer Treatment Reviews63 citations Open access
Semantic Scholar
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study.
L. Provenzano, M. Dieci, G. Curigliano, M. Giuliano +33 more
2025Annals of Oncology40 citations Open access
Semantic Scholar
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study
M. Goetz, I. Çiçin, L. Testa, S. Tolaney +11 more
2024npj Breast Cancer40 citations Open access
Semantic Scholar
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy
P. Squifflet, E. Saad, S. Loibl, M. V. van Mackelenbergh +25 more
2023Journal of Clinical Oncology40 citations
Semantic Scholar
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
D. Massa, C. Vernieri, Lorenzo Nicolè, C. Criscitiello +19 more
2024Journal of the National Cancer Institute38 citations Open access
Semantic Scholar
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
L. Malorni, G. Bianchini, R. Caputo, A. Zambelli +17 more
2023European Journal of Cancer32 citations Open access
Semantic Scholar
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
G. Vernaci, E. Savarino, I. Patuzzi, S. Facchin +12 more
2023The Oncologist30 citations Open access
Semantic Scholar
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
P. Conte, M. Dieci, G. Bisagni, P. Schmid +16 more
2024Journal of Clinical Oncology26 citations
Semantic Scholar
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Anna-Maria Lazaratos, S. Maritan, A. Quaiattini, A. Darlix +20 more
2023Breast26 citations Open access
Semantic Scholar
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
B. Slomovitz, D. Cibula, W. Lv, F. Ortaç +26 more
2024Journal of Clinical Oncology25 citations Open access
Semantic Scholar
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
S. Tolaney, V. Guarneri, Jae Hong Seo, Josefina Cruz +12 more
2024European Journal of Cancer23 citations Open access
Semantic Scholar
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
N. Normanno, A. De Luca, R. E. Abate, A. Morabito +15 more
2023European Journal of Cancer23 citations Open access
Semantic Scholar
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
G. Villacampa, T. Pascual, P. Tarantino, J. Cortés +32 more
2025The Lancet Oncology22 citations
Semantic Scholar
Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review
I. Cosci, V. Salizzato, P. Del Fiore, J. Pigozzo +6 more
2025Pharmaceuticals22 citations Open access
Semantic Scholar
Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study
M.A. Toli, Xingrong Liu, D. Massa, S. Lando +12 more
2025The Lancet Regional Health - Europe17 citations Open access
Semantic Scholar
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
C. Valenza, D. Trapani, S. Gandini, C. Sposetti +14 more
2023European Journal of Cancer17 citations Open access
Semantic Scholar
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
P. Conte, G. Bisagni, F. Piacentini, S. Sarti +17 more
2023Journal of Clinical Oncology17 citations Open access
Semantic Scholar
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer
M. Dieci, G. Bisagni, S. Bartolini, A. Schirone +18 more
2025JAMA Oncology15 citations Open access
Semantic Scholar
Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer
M. Bottosso, F. Miglietta, G. Vernaci, T. Giarratano +3 more
2024Clinical Cancer Research14 citations Open access
Semantic Scholar
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.
F. Miglietta, M. Dieci, T. Giarratano, V. Torri +17 more
2023European Journal of Cancer13 citations Open access
Semantic Scholar
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
M. Dieci, G. Bisagni, S. Bartolini, A. Frassoldati +5 more
2023npj Breast Cancer13 citations Open access
Semantic Scholar
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
E. Hamilton, J. Kim, Natalja Eigėlienė, D. Mavroudis +12 more
2023Journal of Clinical Oncology13 citations Open access
Semantic Scholar
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
F. Miglietta, M. Ragazzi, B. Fernandes, G. Griguolo +17 more
2023Clinical Cancer Research12 citations Open access
Semantic Scholar
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.
F. Miglietta, A. Fabi, D. Generali, M. Dieci +13 more
2023Cancer Treatment Reviews12 citations Open access
Semantic Scholar
Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysis
M. Bottosso, C. Zurlo, F. Miglietta, A. Cattelan +5 more
2025Breast11 citations Open access
Semantic Scholar
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
M. Dieci, P. Conte, G. Bisagni, S. Bartolini +14 more
2023Journal of the National Cancer Institute11 citations Open access
Semantic Scholar
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.
C. Criscitiello, C. Corti, M. de Laurentiis, G. Bianchini +16 more
2023Cancer Treatment Reviews11 citations Open access
Semantic Scholar
Patterns of Comorbidities in Lung Cancer Patients and Survival
Alessandra Buja, M. Di Pumpo, Massimo Rugge, M. Zorzi +8 more
2025Cancers10 citations Open access
Semantic Scholar
Abstract PO2-19-06: An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15
S. Modi, R. Salgado, V. Guarneri, Divi Alagappan +5 more
2024Cancer Research9 citations
Semantic Scholar
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
A. Botticelli, C. Cremolini, S. Scagnoli, M. Biffoni +42 more
2025Clinical Cancer Research8 citations Open access
Semantic Scholar
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
L. Mastrantoni, G. Garufi, G. Giordano, N. Maliziola +26 more
2025npj Breast Cancer8 citations Open access
Semantic Scholar
Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.
P. Conte, G. Bisagni, F. Piacentini, S. Sarti +16 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting
L. Bonanno, M. Lorenzi, D. Massa, M. De Nuzzo +14 more
2023The Oncologist8 citations Open access
Semantic Scholar
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort
L. Visani, I. Ratoša, R. Bartsch, B. Linderholm +18 more
2026Breast7 citations Open access
Semantic Scholar
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
G. Garufi, L. Carbognin, I. Sperduti, F. Miglietta +18 more
2023Therapeutic Advances in Medical Oncology7 citations Open access
Semantic Scholar
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): an Italian Delphi consensus report.
F. Miglietta, M. Razeti, A. Caltavituro, Arianna Dri +31 more
2025Critical reviews in oncology/hematology6 citations Open access
Semantic Scholar
Temporal evolution of breast cancer brain metastases treatments and outcomes
M. Bottosso, G. Griguolo, S. Guiu, M. Guarascio +16 more
2025npj Breast Cancer6 citations Open access
Semantic Scholar
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
G. Pasello, M. Lorenzi, D. Scattolin, A. Del Conte +15 more
2024The Oncologist6 citations Open access
Semantic Scholar
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.
A. Zambelli, L. Cortesi, M. Gaudio, G. Arpino +25 more
2024Cancer Treatment Reviews6 citations Open access
Semantic Scholar
Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2
P. Neven, M. Toi, J. Sohn, Kenichi Inoue +12 more
2025JCO Oncology Advances5 citations Open access
Semantic Scholar
Prospective multicentre study of patients with cutaneous metastases from breast cancer treated with electrochemotherapy
Francesco Russano, G. Corrado, A. Bonadies, E. Migliano +15 more
2025Clinical and Experimental Metastasis5 citations Open access
Semantic Scholar
Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial
F. Miglietta, M. De Graaf, C. Vernieri, F. Piacentini +17 more
2025Clinical Cancer Research5 citations Open access
Semantic Scholar
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data
H. Earl, L. Hiller, J. Dunn, M. Patel +12 more
2025BMJ Oncology5 citations Open access
Semantic Scholar
Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes.
G. Griguolo, M. Bottosso, A. Crema, T. Giarratano +8 more
2025European Journal of Cancer5 citations Open access
Semantic Scholar
HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome.
M. Bottosso, R. Sandoval, B. Verret, Natália Polidorio +8 more
2024European Journal of Cancer5 citations Open access
Semantic Scholar
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
V. Guarneri, J. L. Passos Coelho, F. Duhoux, D. Egle +8 more
2024Future Oncology5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Dieci×22
Invite
M. Dieci — researcher profile on SciRah
F. Miglietta×16
Invite
F. Miglietta — researcher profile on SciRah
G. Griguolo×13
Invite
G. Griguolo — researcher profile on SciRah
L. Del Mastro×9
Invite
L. Del Mastro — researcher profile on SciRah

×9

Invite

F. Puglisi — researcher profile on SciRah

G. Curigliano×8

Invite

G. Curigliano — researcher profile on SciRah

Invite

D. Massa — researcher profile on SciRah

Invite

G. Bisagni — researcher profile on SciRah

G. Bianchini×7

Invite

G. Bianchini — researcher profile on SciRah

Invite

G. Arpino — researcher profile on SciRah

Invite

G. Pruneri — researcher profile on SciRah

Invite

P. Conte — researcher profile on SciRah